Integrated multi-month dispensing of antihypertensive and antiretroviral therapy to sustain hypertension and HIV control.
Journal
Journal of human hypertension
ISSN: 1476-5527
Titre abrégé: J Hum Hypertens
Pays: England
ID NLM: 8811625
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
received:
08
12
2021
accepted:
05
01
2022
revised:
27
12
2021
pubmed:
6
3
2022
medline:
11
3
2023
entrez:
5
3
2022
Statut:
ppublish
Résumé
Multi-month dispensing (MMD) is a patient-centered approach in which stable patients receive medicine refills of three months or more. In this pre-post longitudinal study, we determined hypertension and HIV treatment outcomes in a cohort of hypertensive PLHIV at baseline and 12 months of receiving integrated MMD. At each clinical encounter, one healthcare provider attended to both hypertension and HIV needs of each patient in an HIV clinic. Among the 1,082 patients who received MMD, the mean age was 51 (SD = 9) years and 677 (63%) were female. At the start of MMD, 1,071(98.9%) patients had achieved HIV viral suppression, and 767 (73.5%) had achieved hypertension control. Mean blood pressure reduced from 135/87 (SD = 15.6/15.2) mmHg at the start of MMD to 132/86 (SD = 15.2/10.5) mmHg at 12 months (p < 0.0001). Hypertension control improved from 73.5% to 78.5% (p = 0.01) without a significant difference in the proportion of patients with HIV viral suppression at baseline and at 12 months, 98.9% vs 99.0% (p = 0.65). Patients who received MMD with elevated systolic blood pressure at baseline were less likely to have controlled blood pressure at 12 months (OR-0.9, 95% CI, 0.90,0.92). Overall, 1,043 (96.4%) patients were retained at 12 months. Integrated MMD for stable hypertensive PLHIV improved hypertension control and sustained optimal HIV viral suppression and retention of patients in care. Therefore, it is feasible to provide integrated MMD for both hypertension and HIV treatment and achieve dual control in the setting of sub-Saharan Africa.
Identifiants
pubmed: 35246602
doi: 10.1038/s41371-022-00655-3
pii: 10.1038/s41371-022-00655-3
pmc: PMC8896410
doi:
Substances chimiques
Antihypertensive Agents
0
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
213-219Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
BMJ Glob Health. 2016 Nov 24;1(3):e000055
pubmed: 28588953
Integr Pharm Res Pract. 2017 Jan 27;6:29-35
pubmed: 29354548
Ann Glob Health. 2020 Sep 25;86(1):123
pubmed: 33024709
Hypertension. 2015 Feb;65(2):291-8
pubmed: 25385758
EClinicalMedicine. 2021 Jul 23;38:101039
pubmed: 34368659
Lancet. 2019 Aug 24;394(10199):652-662
pubmed: 31327566
PLoS One. 2020 Jun 5;15(6):e0234049
pubmed: 32502169
Hypertension. 2008 Jun;51(6):1403-19
pubmed: 18391085
Health Aff (Millwood). 2007 Jan-Feb;26(1):13-24
pubmed: 17211010
BMC Public Health. 2019 May 6;19(1):511
pubmed: 31060545
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21650
pubmed: 28770594
Vasc Health Risk Manag. 2014 Jan 16;10:33-44
pubmed: 24476688
J Clin Hypertens (Greenwich). 2018 Oct;20(10):1485-1492
pubmed: 30259642
N Engl J Med. 2019 Jun 20;380(25):2429-2439
pubmed: 30883050
Hypertension. 2007 Dec;50(6):1012-8
pubmed: 17954720
BMC Med. 2020 Mar 27;18(1):75
pubmed: 32216794
Lancet Glob Health. 2021 May;9(5):e628-e638
pubmed: 33865471
Glob Heart. 2021 Feb 04;16(1):9
pubmed: 33598389
BMJ. 2004 Jan 24;328(7433):204
pubmed: 14726370
Pan Afr Med J. 2021 Feb 25;38:216
pubmed: 34046122
BMC Health Serv Res. 2021 May 17;21(1):463
pubmed: 34001123
Circulation. 2016 Aug 9;134(6):441-50
pubmed: 27502908
J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):e58-60
pubmed: 24378724
Circulation. 2016 May 24;133(21):2076-85
pubmed: 27217433
J Acquir Immune Defic Syndr. 2020 Jun 1;84(2):162-172
pubmed: 32097252